CELADON PHARMACEUTICALS PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 102.5 GBX | -2.38% |
|
-10.87% | -10.87% |
| Sales 2021 | - | Sales 2022 | 0.02 2 | Capitalization | 31.14M 2.6B |
|---|---|---|---|---|---|
| Net income 2021 | - 0 | Net income 2022 | -17M -1.42B | EV / Sales 2021 * | - |
| Net cash position 2021 | 4.46M 372M | Net cash position 2022 | 429K 35.77M | EV / Sales 2022 | 1,27,97,59,792 x |
| P/E ratio 2021 * |
-
| P/E ratio 2022 |
-1.71
x | Employees | 24 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 33.86% |
More Fundamentals
* Assessed data
More news
| 1 day | -2.38% | ||
| 1 week | -10.87% | ||
| Current month | +22.02% | ||
| 1 month | +24.24% | ||
| 3 months | +20.59% | ||
| Current year | -10.87% |
1 week
100.00
122.50
1 month
75.00122.50
Current year
75.00122.50
1 year
73.44180.00
3 years
47.50189.00
5 years
47.50189.00
10 years
47.50189.00
| Managers | Title | Age | Since |
|---|---|---|---|
James Short
FOU | Founder | 55 | 01/18/01 |
Jonathan Turner
DFI | Director of Finance/CFO | 46 | 17/23/17 |
Iqbal Gill
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
David Firth
BRD | Director/Board Member | 62 | - |
Ian Anton
CHM | Chairman | 64 | 28/22/28 |
Robert Barr
BRD | Director/Board Member | 65 | 28/22/28 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 102.5 | -2.38% | 42,693 |
| 25/24/25 | 105 | 0.00% | 26,117 |
| 24/24/24 | 105 | -8.70% | 75,712 |
| 23/24/23 | 115 | 0.00% | 90,868 |
| 22/24/22 | 115 | 0.00% | 97,476 |
Delayed Quote London S.E., April 26, 2024 at 09:05 pm IST
More quotes
Celadon Pharmaceuticals Plc is a United Kingdom-based pharmaceutical company. The Company is engaged in research, cultivation, manufacturing, and supply of cannabinoid-based medicines. The Company is focused on growing indoor hydroponic cannabis initially for the chronic pain market. It is also focused on improving the quality of life for chronic pain sufferers, as well as exploring the potential of cannabinoid-based medicines for other conditions, such as autism. The Company's facility comprises an indoor hydroponic cultivation, proprietary GMP extraction and manufacturing and an analytical and R&D laboratory. It also has a minority interest in early-stage biopharma Kingdom therapeutics. The Company's subsidiary, LVL Health is a medical cannabis clinic for chronic pain that owns a medicines and healthcare products regulatory agency (MHRA) conditionally approved cannabis trial using cannabis-based medicinal products to treat chronic pain in the United Kingdom.
Sector
Pharmaceuticals
Calendar
26/09/2024
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.025
GBP
Average target price
2.35
GBP
Spread / Average Target
+129.27%
| 1st Jan change | Capi. | |
|---|---|---|
| -10.87% | 81.98M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- CEL Stock
